...investments already, of which one has so far been disclosed: an €18.5 million series B round in Citryll B.V....

...“Bischofberger Revisits Gilead Castoff” ). Eric Meldrum and Paul-Peter Tak have joined the board of Citryll B.V....

...ADCs) in Phase I-III testing. Citryll raises €15M series A from Chinese and Dutch investors Citryll B.V....
...L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). Elizabeth S. Eaton, Staff Writer Calliditas Therapeutics AB Citryll B.V. Jiangsu...

...few weeks." Antibodies that deplete neutrophils or target NETs may also represent new flu therapeutics. Citryll B.V....
...develop a caspase-1 inhibitor. Companies and Institutions Mentioned Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Citryll B.V....

...have fewer side effects than PAD inhibitors already in development. Last month, ModiQuest spun out Citryll B.V....
...the normal function of PAD enzymes, and so have a decreased likehood for adverse effects," Citryll...
...fibrosis. Citryll has an exclusive option to license the IP portfolio. Companies and Institutions Mentioned Citryll B.V....